Wednesday, 10 December 2025
  
Login

Australia's most trusted
source of pharma news

Wednesday, 10 December 2025
News

Data justifies hefty drug price tag

Posted 9 December 2025 AM

CSL has got some new ammunition to support a premium price for its gene therapy when it negotiates with the government over funding.

MSAC supported public funding for haemophilia b gene therapy Hemgenix under the National Blood Agreement last month, but at a lower price than sought by CSL. Hemgenix is the world's second most expensive drug, sold overseas for around $5.3 million, but the Committee said the four-year follow-up data did not support the durability of the treatment over a lifetime.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (12)

Clinical & Medical, R&D (9)

Regulatory, Pharmacovigilance & QA (3)

Devices (1)

Other (13)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.